A carregar...
Publicação
FDA boosts the Progressive Supranuclear Palsy Rating Scale!
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 97.68 KB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
Gewily et al report on the significant modification of the well-established progressive supranuclear palsy
rating scale (PSPRS), a process that was prompted and guided by feedback from the United States Food
and Drug Administration (FDA). This study comprehensively compared the original (full PSPRS, 28 items)
and the shortened only and shortened and rescored (PSPRS-10 and rPSPRS-10) versions of the PSPRS
using item response theory (IRT). The study used data from 979 patients across four interventional clinical
trials and two registries. The findings revealed that the PSPRS-10 contained 76% of the information from
the full scale while demonstrating better unidimensionality and inter-item correlation. Some items in the full
PSPRS showed poor correlation with disease severity, supporting the reduced scale to evaluate longitudinal
disease progression. Power analyses indicated that PSPRS-10 was more effective than rPSPRS-10 in
detecting treatment effects. The study concludes that focusing on the PSPRS-10 items is justified for
assessing PSP severity and treatment effects in clinical trials, although rescoring may potentially weaken its
sensitivity.
Descrição
© 2024 International Parkinson and Movement Disorder Society.
Palavras-chave
Contexto Educativo
Citação
Mov Disord. 2024 Dec;39(12):2127-2129
Editora
Wiley